Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants
Copyright © 2021. Published by Elsevier Ltd..
COVID-19 pandemic has severely impacted the public health and social economy worldwide. A safe, effective, and affordable vaccine against SARS-CoV-2 infections/diseases is urgently needed. We have been developing a recombinant vaccine based on a prefusion-stabilized spike trimer of SARS-CoV-2 and formulated with aluminium hydroxide and CpG 7909. The spike protein was expressed in Chinese hamster ovary (CHO) cells, purified, and prepared as a stable formulation with the dual adjuvant. Immunogenicity studies showed that candidate vaccines elicited robust neutralizing antibody responses and substantial CD4+ T cell responses in both mice and non-human primates. And vaccine-induced neutralizing antibodies persisted at high level for at least 6 months. Challenge studies demonstrated that candidate vaccine reduced the viral loads and inflammation in the lungs of SARS-CoV-2 infected golden Syrian hamsters significantly. In addition, the vaccine-induced antibodies showed cross-neutralization activity against B.1.1.7 and B.1.351 variants. These data suggest candidate vaccine is efficacious in preventing SARS-CoV-2 infections and associated pneumonia, thereby justifying ongoing phase I/II clinical studies in China (NCT04982068 and NCT04990544).
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
---|---|
Enthalten in: |
Vaccine - 39(2021), 48 vom: 26. Nov., Seite 7001-7011 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liu, Haitao [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 26.11.2021 Date Revised 29.11.2021 published: Print-Electronic ClinicalTrials.gov: NCT04982068, NCT04990544 Citation Status MEDLINE |
---|
doi: |
10.1016/j.vaccine.2021.10.066 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM332880397 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM332880397 | ||
003 | DE-627 | ||
005 | 20231225220503.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.vaccine.2021.10.066 |2 doi | |
028 | 5 | 2 | |a pubmed24n1109.xml |
035 | |a (DE-627)NLM332880397 | ||
035 | |a (NLM)34750014 | ||
035 | |a (PII)S0264-410X(21)01399-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Liu, Haitao |e verfasserin |4 aut | |
245 | 1 | 0 | |a Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.11.2021 | ||
500 | |a Date Revised 29.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a ClinicalTrials.gov: NCT04982068, NCT04990544 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
520 | |a COVID-19 pandemic has severely impacted the public health and social economy worldwide. A safe, effective, and affordable vaccine against SARS-CoV-2 infections/diseases is urgently needed. We have been developing a recombinant vaccine based on a prefusion-stabilized spike trimer of SARS-CoV-2 and formulated with aluminium hydroxide and CpG 7909. The spike protein was expressed in Chinese hamster ovary (CHO) cells, purified, and prepared as a stable formulation with the dual adjuvant. Immunogenicity studies showed that candidate vaccines elicited robust neutralizing antibody responses and substantial CD4+ T cell responses in both mice and non-human primates. And vaccine-induced neutralizing antibodies persisted at high level for at least 6 months. Challenge studies demonstrated that candidate vaccine reduced the viral loads and inflammation in the lungs of SARS-CoV-2 infected golden Syrian hamsters significantly. In addition, the vaccine-induced antibodies showed cross-neutralization activity against B.1.1.7 and B.1.351 variants. These data suggest candidate vaccine is efficacious in preventing SARS-CoV-2 infections and associated pneumonia, thereby justifying ongoing phase I/II clinical studies in China (NCT04982068 and NCT04990544) | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Subunit vaccine | |
650 | 4 | |a Trimeric spike protein | |
650 | 7 | |a Alum Compounds |2 NLM | |
650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
650 | 7 | |a aluminum sulfate |2 NLM | |
650 | 7 | |a 34S289N54E |2 NLM | |
650 | 7 | |a Aluminum Hydroxide |2 NLM | |
650 | 7 | |a 5QB0T2IUN0 |2 NLM | |
700 | 1 | |a Zhou, Chenliang |e verfasserin |4 aut | |
700 | 1 | |a An, Jiao |e verfasserin |4 aut | |
700 | 1 | |a Song, Yujiao |e verfasserin |4 aut | |
700 | 1 | |a Yu, Pin |e verfasserin |4 aut | |
700 | 1 | |a Li, Jiadai |e verfasserin |4 aut | |
700 | 1 | |a Gu, Chenjian |e verfasserin |4 aut | |
700 | 1 | |a Hu, Dongdong |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Yuanxiang |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Lingli |e verfasserin |4 aut | |
700 | 1 | |a Huang, Chuanqi |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Chao |e verfasserin |4 aut | |
700 | 1 | |a Yang, Yunqi |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Qianjun |e verfasserin |4 aut | |
700 | 1 | |a Wang, Dekui |e verfasserin |4 aut | |
700 | 1 | |a Liu, Yuqiang |e verfasserin |4 aut | |
700 | 1 | |a Miao, Chenyang |e verfasserin |4 aut | |
700 | 1 | |a Cao, Xiayao |e verfasserin |4 aut | |
700 | 1 | |a Ding, Longfei |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Yuanfei |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Hua |e verfasserin |4 aut | |
700 | 1 | |a Bao, Linlin |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Lingyun |e verfasserin |4 aut | |
700 | 1 | |a Yan, Huan |e verfasserin |4 aut | |
700 | 1 | |a Fan, Jiang |e verfasserin |4 aut | |
700 | 1 | |a Xu, Jianqing |e verfasserin |4 aut | |
700 | 1 | |a Hu, Zhongyu |e verfasserin |4 aut | |
700 | 1 | |a Xie, Youhua |e verfasserin |4 aut | |
700 | 1 | |a Liu, Jiangning |e verfasserin |4 aut | |
700 | 1 | |a Liu, Ge |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 39(2021), 48 vom: 26. Nov., Seite 7001-7011 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
773 | 1 | 8 | |g volume:39 |g year:2021 |g number:48 |g day:26 |g month:11 |g pages:7001-7011 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2021.10.066 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 39 |j 2021 |e 48 |b 26 |c 11 |h 7001-7011 |